Vitamin D Status and Parkinson’s Disease

Barichella, Michela; Garrì, Federica; Caronni, Serena; Bolliri, Carlotta; Zocchi, Luciano; Macchione, Maria Carmela; Ferri, Valentina; Calandrella, Daniela; Pezzoli, Gianni

doi:10.3390/brainsci12060790

Cited by 26 publications

(23 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is further confirmed by the present study, which is in line with the available literature and with its heterogeneity ( 3 ). The latter is probably caused by differences in the demographic sample characteristics, in the outcome measures, and by the biological variability of the 25(OH)D and PTH metabolism over time, during seasons due to light exposure, but also age and sex ( 9 ). Our real-life study was conducted on a mild-to-moderate sample of patients with PD during the winter season when vitamin D levels are putative to be lower with a possible increase in PTH than in other periods of the year.…”

Section: Discussionmentioning

confidence: 99%

Leg restlessness and hyperparathyroidism in Parkinson's disease, a further clue to RLS pathogenesis?

Marano

Pozzilli²,

Magliozzi³

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

BackgroundNon-motor manifestations are the main features of Parkinson's disease (PD). These have been associated with vitamin D abnormalities, but the role of parathormone (PTH) is still obscure. Among the non-motor symptoms of PD, the pathogenesis of restless leg syndrome (RLS) is still debated, but it has been associated with the vitamin D/PTH axis in other disease models. Our study deepens the association between vitamin D and PTH with the prevalence of non-motor symptoms of PD and explores such a relationship in patients reporting leg restlessness.MethodsFifty patients with PD were extensively investigated with motor and non-motor scales. Data on serum levels of vitamin D, PTH, and related metabolites were obtained, and patients were stratified as having vitamin D deficiency or hyperparathyroidism according to standardized criteria.ResultsOverall, 80% of patients with PD exhibited low vitamin D levels, and hyperparathyroidism was diagnosed in 45%. The analysis of the non-motor symptoms profile using the non-motor symptom questionnaire (NMSQ) revealed 36% of leg restlessness, a main feature of RLS. This was significantly associated with worse motor symptoms, quality of sleep, and quality of life. Moreover, it was associated with hyperparathyroidism (OR: 3.48) and with PTH levels, independent of vitamin D, calcium/phosphate levels, and motor status.ConclusionOur results suggest a significant association between the vitamin D/PTH axis and leg restlessness in PD. PTH has a putative role in nociceptive modulation, and previous evidence on hyperparathyroidism has suggested a possible interrelation with RLS. Further investigations are necessary to add PTH to the non-dopaminergic non-motor landscape of PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Leg restlessness and hyperparathyroidism in Parkinson's disease, a further clue to RLS pathogenesis?

Marano

Pozzilli²,

Magliozzi³

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…A correlation between vitamin D levels, neurodegenerative diseases, and cognitive status is well-known in recent literature. For example, vitamin D levels are reported to be lower than expected values in Alzheimer's disease and other dementias [44,45] and in Parkinson's disease (PD) [46,47], where lower levels of vitamin D can represent a biomarker of risk of mild cognitive impairment (MCI) development in PD patients [48]. Furthermore, improvements in cognitive functions have been reported after supplementation in patients with MCI and Alzheimer's disease [49,50].…”

Section: Discussionmentioning

confidence: 99%

Potential role of vitamin D levels in amyotrophic lateral sclerosis cognitive impairment

et al. 2023

View full text Add to dashboard Cite

Cognitive impairment (CI) is common in amyotrophic lateral sclerosis (ALS): a keystone is identifying factors that could potentially modify the CI course. In recent years, vitamin D is becoming a potential modificatory factor for CI in many neurological disorders. This study aimed to highlight if vitamin D deficiency correlated with CI and clinical features in a cohort of ALS patients. We included 55 ALS patients with a neuropsychological evaluation (classified with the Strong Criteria) and a vitamin D dosage at the diagnosis. We also reviewed medical records and completed data for medical history, physical and neurological examination, and functional scales. At the diagnosis, 30 patients (54%) had CI. Most patients (82%) displayed low vitamin D levels (19.87 ± 9.80 ng/ml). Comparing the vitamin D level between patients with and without CI, we observed significantly lower values in the first group (15.8 ± 8.2 vs. 22.0 ± 9.7 ng/ml, p: 0.04). In the spinal female subgroup (n = 15), we found an inverse correlation between vitamin D and bizarreness score in the cognitive estimates test (r = 0.58; p: 0.04) and a positive correlation with the Corrected Raven’s Standard Progressive Matrices (r = 0.53, p: 0.04). Conversely, in the bulbar female group, we observed a correlation with the corrected direct span (r = 0.84, p: 0.03). With the log-rank survival analysis, we found that the patients with vitamin D < 10 ng/ml had a shorter disease duration (Chi: 5.78, p: 0.02). Our results indicate that levels of vitamin D can influence the cognitive status of people living with ALS and that severe deficits might be an adverse prognostic survival factor.

show abstract

“…It has recently been shown that decreased levels of vitamin D leads to apoptosis of dopaminergic neurons, while its systemic administration counterbalances the process ( 55 ). In addition, growing evidence suggests that vitamin D may become a feasible biomarker for PD, but larger cohort studies are required ( 56 ).…”

Section: Appraising the Risk Of Heart Disease In Patients With Pdmentioning

confidence: 99%

Parkinson's disease and cardiovascular involvement: Edifying insights (Review)

Grosu

Crişan

et al. 2023

Biomed Rep

View full text Add to dashboard Cite

Parkinson's disease (PD) is one of the most common neurodegenerative illnesses, and is a major healthcare burden with prodigious consequences on life-quality, morbidity, and survival. Cardiovascular diseases are the leading cause of mortality worldwide and growing evidence frequently reports their co-existence with PD. Cardiac dysautonomia due to autonomic nervous system malfunction is the most prevalent type of cardiovascular manifestation in these patients, comprising orthostatic and postprandial hypotension, along with supine and postural hypertension. Moreover, many studies have endorsed the risk of patients with PD to develop ischemic heart disease, heart failure and even arrhythmias, but the underlying mechanisms are not entirely clear. As importantly, the medication used in treating PD, such as levodopa, dopamine agonists or anticholinergic agents, is also responsible for cardiovascular adverse reactions, but further studies are required to elucidate the underlying mechanisms. The purpose of this review was to provide a comprehensive overview of current available data regarding the overlapping cardiovascular disease in patients with PD. Contents1. Background 2. Cardiovascular dysautonomia in patients with PD 3. Appraising the risk of heart disease in patients with PD 4. PD therapy related to cardiovascular disease 5. Conclusion

show abstract

Vitamin D Status and Parkinson’s Disease

Cited by 26 publications

References 118 publications

Leg restlessness and hyperparathyroidism in Parkinson's disease, a further clue to RLS pathogenesis?

Leg restlessness and hyperparathyroidism in Parkinson's disease, a further clue to RLS pathogenesis?

Potential role of vitamin D levels in amyotrophic lateral sclerosis cognitive impairment

Parkinson's disease and cardiovascular involvement: Edifying insights (Review)

Contact Info

Product

Resources

About